Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Doi, Toshiki ^a   Doi, Shigehiro ^a   Nakashima, Ayumu ^a   Ueno, Toshinori ^a   Yokoyama, Yukio ^a   Kohno, Nobuoki ^b   Masaki, Takao ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL; INTERLEUKIN 1BETA CONVERTING ENZYME; LEUCINE; MIZORIBINE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM CHLORIDE; UNCLASSIFIED DRUG; DNA NUCLEOTIDYLEXOTRANSFERASE; INORGANIC SALT; RIBONUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HYPERTENSION; KIDNEY FIBROSIS; MALE; NEPHRITIS; NICK END LABELING; NONHUMAN; NUCLEOTIDE BINDING SITE; OLIGOMERIZATION; PROTEIN EXPRESSION; PYROPTOSIS; RAT; UNINEPHRECTOMY; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; INFLAMMATION; KIDNEY; KIDNEY DISEASES; METABOLISM; SPRAGUE DAWLEY RAT;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CASPASE 1; DNA NUCLEOTIDYLEXOTRANSFERASE; EPITHELIAL SODIUM CHANNELS; FIBROSIS; HYPERTENSION; INFLAMMATION; KIDNEY; KIDNEY DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOSIDES; SALTS; SODIUM CHLORIDE;

EID: 84898877351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093513     Document Type: Article

References (46)

1. Booth RE, Johnson JP, Stockand JD (2002) Aldosterone. Adv Physiol Educ 26: 8-20.
2. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, et al. (2003) Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021-1026. (Pubitemid 36548598)
3. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, et al. (2004) Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93: 990-996. (Pubitemid 38479452)
4. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, et al. (2006) Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1: 940-951.
5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709-717. (Pubitemid 29407370)
6. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321. (Pubitemid 36384098)
7. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, et al. (2010) Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 332: 1072-1080.
8. de las Heras N, Ruiz-Ortega M, Miana M, Rupérez M, Sanz-Rosa D, et al. (2007) Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 25: 629-638. (Pubitemid 46213802)
9. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, et al. (2006) Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093. (Pubitemid 44289165)
10. Ikeda H, Tsuruya K, Toyonaga J, Masutani K, Hayashida H, et al. (2009) Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 75: 147-155.
11. Feria I, Pichardo I, Juárez P, Ramírez V, González MA, et al. (2003) Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43-52. (Pubitemid 35463905)
12. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, et al. (2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227.
13. Heptinstall RH, Hill GS (1967) Steroid-induced hypertension in the rat. A study of the effects of renal artery constriction on hypertension caused by deoxycorticosterone. Lab Invest. 16: 751-767.
14. Rodríguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ (2012) Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol 39: 96-103.
15. Lee SB, Kalluri R (2010) Mechanistic connection between inflammation and fibrosis. Kidney Int 78: S22-S26.
16. Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7: 99-109.
17. Anders HJ, Muruve DA (2011) The inflammasomes in kidney disease. J Am Soc Nephrol 22: 1007-1018.
18. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, et al. (2003) Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 35: 685-694. (Pubitemid 36677452)
19. Schielke GP, Yang GY, Shivers BD, Betz AL (1998) Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab 18: 180-185. (Pubitemid 28082515)
20. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA (2001) IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 98: 13249-13254. (Pubitemid 33051348)
21. Li P, Allen H, Banerjee S, Franklin S, Herzog L, et al. (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80: 401-411.
22. Kawasaki Y (2009) Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol 2009: 681482.
23. Ueno T, Nakashima A, Doi S, Kawamoto T, Honda K, et al. (2013) Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling. Kidney Int 84: 297-307.
24. Doi S, Zou Y, Togao O, Pastor JV, John GB, et al. (2011) Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286: 8655-8665.
25. Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 9: 459-469.
26. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, et al. (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259: 1739-1742. (Pubitemid 23114658)
27. Cavaillon JM (1994) Cytokines and macrophages. Biomed Pharmacother 48: 445-453.
28. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM (2008) TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76-R83.
29. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, et al. (2007) Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. Hypertension 50: 1069-1076. (Pubitemid 350172928)
30. Furuichi K, Wada T, Iwata Y, Kitagawa K, Kobayashi K, et al. (2003) CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 14: 2503-2515. (Pubitemid 37169336)
31. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, et al. (2004) Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 165: 237-246. (Pubitemid 38821831)
32. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, et al. (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772-777. (Pubitemid 47077388)
33. Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, et al. (2009) Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol 20: 131-144.
34. Terada Y, Ueda S, Hamada K, Shimamura Y, Ogata K, et al. (2012) Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. Clin Exp Nephrol 16: 81-88.
35. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, et al. (2012) Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36: 401-414.
36. Zhang A, Jia Z, Wang N, Tidwell TJ, Yang T (2011) Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney Int 80: 51-60.
37. Schrier RW (2010) Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol. 6: 61
38. Soundararajan R, Pearce D, Hughey RP, Kleyman TR (2010) Role of epithelial sodium channels and their regulators in hypertension. J Biol Chem 285: 30363-30369.
39. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, et al. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460. (Pubitemid 47529329)
40. Zhang A, Jia Z, Guo X, Yang T (2007) Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 293: F723-F731. (Pubitemid 47403342)
41. Cheng J, Truong LD, Wu X, Kuhl D, Lang F, et al. (2010) Serum- and glucocorticoid-regulated kinase 1 is upregulated following unilateral ureteral obstruction causing epithelial-mesenchymal transition. Kidney Int 78: 668-678.
42. Hill GS (2008) Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 17: 266-270.
43. Shimizu M, Shou I, Tsuge T, Abe M, Tomino Y (1998) Effect of mizoribine on glomerulonephritis of early-stage IgA nephropathy in ddY mice. Nephron. 79: 67-72. (Pubitemid 28204041)
44. Sakai T, Kawamura T, Shirasawa T (1997) Mizoribine improves renal tubulointerstitial fibrosis in unilateral ureteral obstruction (UUO)-treated rat by inhibiting the infiltration of macrophages and the expression of alpha-smooth muscle actin. J Urol. 158: 2316-2322. (Pubitemid 27481397)
45. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, et al. (2005) Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant. 20: 1573-1581. (Pubitemid 41418579)
46. Takahashi S, Taniguchi Y, Nakashima A, Arakawa T, Kawai T, et al. (2009) Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model. Nephron Exp Nephrol. 112: e59-e69.